14 / 26
Page 69
Journal of Infectious Diseases and Treatment
ISSN: 2472-1093
7
t h
E u r o s c i c o n C o n f e r e n c e o n
Clinical Pathology
and Epidemiology
F e b r u a r y 2 7 - 2 8 , 2 0 1 9
P r a g u e , C z e c h R e p u b l i c
Clinical Pathology & Epidemiology 2019
Background:
Current cancer register of Uzbekistan demonstrates that prostate cancer is the 5th leading cause of mortality. The
lower incidence of disease in comparison with European countries could be due to the gaps in diagnosis, especially in pathology.
Discovering the most useful and at the same time financially effective amount of immunohistochemistry (IHC) markers remain
as the challenged topic in developing countries.
Purpose:
The objective of this study is to evaluate the use of the p63 and AMACR in clarifying suspicious foci in prostatic needle
biopsy specimens.
Materials:
A total of 180 cases are selected from Jan’2017 to Oct’ 2018. All cases were reviewed and divided into three groups.
Benign (85), cases with suspicious foci (23 cases) and malignant (72 cases). IHC was carried out using monoclonal AMACR and
p63 antibodies in the 23 suspicious cases along with positive and negative controls.
Results:
This study showed AMACR had a sensitivity of 92%, specificity of 94%, whereas p63 had a sensitivity of 94%, specificity
of 100%. All the 23 suspicious cases were resolved by using a combination of morphology and IHC expression p63 and AMACR.
In nine cases (9/23), diagnosis was changed from the benign to malignant. In two cases, benign to high grade prostatic
intraepithelial neoplasia (2/23) and in five cases from malignant to benign (5/23). This change was statistically significant with
P value of 0.0011.
Conclusions:
Histopathological exanimation is the gold standard and ordering immunohistochemistry prospectively is not
necessary in all cases of prostatic needle biopsies. Our recommendation is the use of p63 in cases of morphologically ambiguous
prostate biopsies and take into account that if expression would be aberrant (which occurs in <1%) than go to AMACR and
accordingly utility of just one IHC marker would be economically beneficial for countries with limited financial resources.
gulrukhbotiralieva@gmail.comPathologic issues in interpretation of prostate
needle core biopsies in developing countries:
multicenter retrospective analysis
Botiralieva G
1,2
, Muratov A
1,2
and Rakhimova B
2
1
Tashkent Medical Academy, Oezbekistan
2
IPSUM Pathology, Oezbekistan
J Infec Dis Treat 2019, Volume: 5
DOI: 10.21767/2472-1093-C1-009